JP2017526629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526629A5 JP2017526629A5 JP2016575341A JP2016575341A JP2017526629A5 JP 2017526629 A5 JP2017526629 A5 JP 2017526629A5 JP 2016575341 A JP2016575341 A JP 2016575341A JP 2016575341 A JP2016575341 A JP 2016575341A JP 2017526629 A5 JP2017526629 A5 JP 2017526629A5
- Authority
- JP
- Japan
- Prior art keywords
- htr
- type
- hematological malignancy
- subject
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 16
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 15
- 206010066476 Haematological malignancy Diseases 0.000 claims 13
- 238000000338 in vitro Methods 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 210000001185 bone marrow Anatomy 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382249.2A EP2959904A1 (en) | 2014-06-27 | 2014-06-27 | Methods for treating, diagnosing and prognosing a haematological malignancy |
| EP14382249.2 | 2014-06-27 | ||
| PCT/EP2015/064571 WO2015197839A1 (en) | 2014-06-27 | 2015-06-26 | Methods for treating, diagnosing and prognosing a haematological malignancy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019451A Division JP6846551B2 (ja) | 2014-06-27 | 2020-02-07 | 血液系悪性腫瘍を治療、診断および予後判定するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526629A JP2017526629A (ja) | 2017-09-14 |
| JP2017526629A5 true JP2017526629A5 (enExample) | 2018-12-06 |
Family
ID=51162662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575341A Withdrawn JP2017526629A (ja) | 2014-06-27 | 2015-06-26 | 血液系悪性腫瘍を治療、診断および予後判定するための方法 |
| JP2020019451A Active JP6846551B2 (ja) | 2014-06-27 | 2020-02-07 | 血液系悪性腫瘍を治療、診断および予後判定するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019451A Active JP6846551B2 (ja) | 2014-06-27 | 2020-02-07 | 血液系悪性腫瘍を治療、診断および予後判定するための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10195207B2 (enExample) |
| EP (2) | EP2959904A1 (enExample) |
| JP (2) | JP2017526629A (enExample) |
| KR (1) | KR102628235B1 (enExample) |
| CN (1) | CN106471373B (enExample) |
| AU (2) | AU2015279105B2 (enExample) |
| BR (1) | BR112016029562B1 (enExample) |
| CA (1) | CA2953272C (enExample) |
| DK (1) | DK3160472T3 (enExample) |
| ES (1) | ES2796056T3 (enExample) |
| IL (1) | IL249579B (enExample) |
| MX (1) | MX362049B (enExample) |
| RU (1) | RU2727418C2 (enExample) |
| WO (1) | WO2015197839A1 (enExample) |
| ZA (1) | ZA201700080B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3490554B1 (en) * | 2016-07-28 | 2023-07-05 | Jiangsu Yahong Meditech Co., Ltd. | Uses of dopamine beta-hydroxylase (dbh) inhibitors for the treatment of cancer |
| EP3348266A1 (en) * | 2017-01-16 | 2018-07-18 | Leukos Biotech, S.L. | Combination therapy for treating cancer |
| JP7002245B2 (ja) * | 2017-08-10 | 2022-01-20 | シスメックス株式会社 | 血液分析装置、血液分析方法およびプログラム |
| US11426408B2 (en) * | 2017-11-01 | 2022-08-30 | National University Of Singapore | Use of serotonergic drugs to treat virus-induced thrombocytopenia |
| HUE070062T2 (hu) | 2018-01-18 | 2025-05-28 | Leukos Biotech S L | Apomorfin-palmitinsav kokristály szilárd részecske kristályos forma |
| US11034751B1 (en) | 2018-01-30 | 2021-06-15 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using serotonin receptor inhibitors |
| CN111257558B (zh) * | 2020-01-19 | 2021-08-24 | 江苏省人民医院（南京医科大学第一附属医院） | 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155669A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| NL300886A (enExample) | 1962-11-23 | |||
| US3471515A (en) | 1965-02-01 | 1969-10-07 | Sandoz Ag | (2-hydroxy-3-substituted aminopropoxy)indoles |
| US3466325A (en) | 1965-04-30 | 1969-09-09 | Haessle Ab | 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof |
| DE1668055B2 (de) | 1967-03-10 | 1973-09-06 | Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt | Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung |
| GB1308191A (en) | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| GB0202337D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Birmingham | Cancer treatment |
| KR20040055311A (ko) * | 2002-12-20 | 2004-06-26 | 주식회사 피앤아이 컨설팅 | 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템 |
| EP1597589B1 (en) * | 2003-02-17 | 2008-06-04 | Bayer HealthCare AG | Diagnostics and therapeutics for haematological diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f) |
| WO2008098351A1 (en) * | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| WO2008146101A1 (en) * | 2007-06-01 | 2008-12-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ligands of hvem for treating hematologic malignancies and autoimmune diseases |
| ES2689322T3 (es) * | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| WO2010135468A1 (en) * | 2009-05-19 | 2010-11-25 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| WO2015079439A1 (en) * | 2013-11-26 | 2015-06-04 | Technion Research And Development Foundation Limited | Neuronal modulation |
| US20150197839A1 (en) * | 2014-01-13 | 2015-07-16 | Maria Celeste Rellamas Tria | Forming conductive pattern using titania sol-gel |
-
2014
- 2014-06-27 EP EP14382249.2A patent/EP2959904A1/en not_active Withdrawn
-
2015
- 2015-06-26 MX MX2016016994A patent/MX362049B/es active IP Right Grant
- 2015-06-26 KR KR1020167035701A patent/KR102628235B1/ko active Active
- 2015-06-26 RU RU2016147748A patent/RU2727418C2/ru active
- 2015-06-26 CA CA2953272A patent/CA2953272C/en active Active
- 2015-06-26 JP JP2016575341A patent/JP2017526629A/ja not_active Withdrawn
- 2015-06-26 EP EP15731945.0A patent/EP3160472B1/en active Active
- 2015-06-26 DK DK15731945.0T patent/DK3160472T3/da active
- 2015-06-26 BR BR112016029562-5A patent/BR112016029562B1/pt active IP Right Grant
- 2015-06-26 ES ES15731945T patent/ES2796056T3/es active Active
- 2015-06-26 AU AU2015279105A patent/AU2015279105B2/en not_active Expired - Fee Related
- 2015-06-26 CN CN201580033662.1A patent/CN106471373B/zh active Active
- 2015-06-26 WO PCT/EP2015/064571 patent/WO2015197839A1/en not_active Ceased
- 2015-06-26 US US15/322,012 patent/US10195207B2/en active Active
-
2016
- 2016-12-15 IL IL249579A patent/IL249579B/en active IP Right Grant
-
2017
- 2017-01-04 ZA ZA2017/00080A patent/ZA201700080B/en unknown
-
2018
- 2018-12-11 US US16/216,701 patent/US11337984B2/en active Active
-
2020
- 2020-01-02 AU AU2020200010A patent/AU2020200010B2/en active Active
- 2020-02-07 JP JP2020019451A patent/JP6846551B2/ja active Active
- 2020-09-08 US US17/014,738 patent/US20210228593A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,199 patent/US20220323456A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526629A5 (enExample) | ||
| NZ746139A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| MY199017A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| TN2015000452A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
| BR112018074406A2 (pt) | métodos para o tratamento de malignidades de células b utilizando terapia celular adotiva | |
| RU2013146242A (ru) | Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов | |
| TN2013000468A1 (en) | Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| JO3733B1 (ar) | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة | |
| MD20130089A2 (ro) | Metodă de tratament al mielomului multiplu | |
| JP2015525207A5 (enExample) | ||
| WO2017024019A8 (en) | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies | |
| MX2016007179A (es) | Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. | |
| MX2021014963A (es) | Metodos para predecir el beneficio terapeutico de la terapia con anti-cd19 en pacientes. | |
| JP2017503481A5 (enExample) | ||
| EA201490800A1 (ru) | Способ ингибирования деубиквитинирующей активности | |
| JP2018527570A5 (enExample) | ||
| RU2016147748A (ru) | Способы лечения, диагностики и прогнозирования гематологического злокачественного новообразования | |
| WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
| EP4328319A3 (en) | Methods and compositions for identifying and treating patients with small cell lung cancer | |
| AR100734A1 (es) | Método para tratar leucemia linfocítica crónica (cll) | |
| WO2014071218A3 (en) | Biomarkers for breast cancer and methods of using same | |
| JP2011507880A5 (enExample) | ||
| RU2013135809A (ru) | Способ прогнозирования эффективности химиотерапии у больных со злокачественными новообразованиями эпителиальных тканей | |
| Kim et al. | Inadvertent potential risk of neoadjuvant chemotherapy in cervical cancer |